|
|
||||||||
J Thorac Cardiovasc Surg 2004;127:1068-1077
© 2004 The American Association for Thoracic Surgery
Cardiopulmonary support and physiology |
, MDc
a Department of Biomedical Engineering, Lerner Research Institute, Cleveland, Ohio, USA
b Department of Thoracic and Cardiovascular Surgery, Kaufman Center for Heart Failure, Cleveland, Ohio, USA
c Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Read at the Eighty-third Annual Meeting of The American Association for Thoracic Surgery, Boston, Mass, May 4-7, 2003.
Received for publication May 1, 2003; revisions received November 19, 2003; accepted for publication December 1, 2003.
* Address for reprints: Kiyotaka Fukamachi, MD, PhD, Department of Biomedical Engineering/ND20, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
fukamach{at}bme.ri.ccf.org
OBJECTIVE:: We evaluated the capability of the Myocor Coapsys device (Myocor, Inc, Maple Grove, Minn) to reduce functional mitral regurgitation in a canine model of dilated cardiomyopathy.
METHODS: Functional mitral regurgitation with heart failure was induced in 7 dogs by rapid ventricular pacing. The Coapsys device, which consists of anterior and posterior epicardial pads connected by a subvalvular chord, was then implanted. Heart failure was maintained by continued pacing for 8 weeks. Hemodynamic and echocardiographic measurements were performed at pre- and postsizing and after 8 weeks. The Coapsys subvalvular chord was cut to verify that maintenance of valve competency was due to the device.
RESULTS: All implants were performed off-pump without atriotomy. Mitral regurgitation was reduced in all animals; mean mitral regurgitation grade was reduced from 2.9 ± 0.7 to 0.7 ± 0.8 (P = .00005) and was maintained at 0.8 ± 0.8 after 8 weeks, without hemodynamic compromise or structural damage to the mitral valve. Mitral regurgitation returned to 3.6 ± 0.8 (P = .102 versus presizing) after cutting the Coapsys subvalvular chord.
CONCLUSION: The Coapsys device consistently and chronically reduced functional mitral regurgitation. This device is in clinical trials in the United States.
This article has been cited by other articles:
![]() |
M. Akiyama, Z. B. Popovic, K. Kamohara, F. Cingoz, M. Daimon, C. Ootaki, Y. Ootaki, M. Martin, J. Liu, M. W. Kopcak Jr, et al. Acute reduction of functional mitral regurgitation in canine model using an epicardial device. Ann. Thorac. Surg., May 1, 2008; 85(5): 1771 - 1775. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Langer, F. Rodriguez, S. Ortiz, A. Cheng, T. C. Nguyen, M. K. Zasio, D. Liang, G. T. Daughters, N. B. Ingels, and D. C. Miller Subvalvular Repair: The Key to Repairing Ischemic Mitral Regurgitation? Circulation, August 30, 2005; 112(9_suppl): I-383 - I-389. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Levine and E. Schwammenthal Ischemic Mitral Regurgitation on the Threshold of a Solution: From Paradoxes to Unifying Concepts Circulation, August 2, 2005; 112(5): 745 - 758. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |